Even with the rise of AI and big data in biopharma, turning multi-omics data into real-world impact is still a challenge. Issues like biologics workflow complexity, scattered data, and inconsistent pipeline standards continue to slow R&D and drive up costs - especially in areas like antibody development, biomarker discovery, and clinical trials.

Elucidata works with leading biotech and pharma teams to solve this. Whether it’s integrating platforms like Genedata, managing complex biologics data, or powering AI-ready workflows with Polly, we help teams move faster and make smarter decisions. We’ve helped customers dramatically reduce manual effort in protein production workflows, accelerating antibody development and delivered major cost savings by leveraging highly curated public data to enhance AI-driven drug discovery collaborations. Our data centric AI platform platform, Polly, helps automate complex biologics workflows, streamline data preparation, and accelerate decisions across biomarker discovery, genomics, and translational research.

If you're looking to boost the ROI of your research data, leverage multi-modal datasets, or enable high-throughput data analytics in drug discovery, let’s meet at BIO 2025. Our CEO and Co-founder Abhishek Jha will be attending and is eager to connect with biotech leaders, scientists, and senior enterprise data leaders to discuss real-world use cases and partnership opportunities.